Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544330 | 0.92 | MAPT (0.50) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1544120 | 0.92 | MAPT (0.50) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1543858 | 0.92 | CYP3A4 (0.46) | CYP3A4LMNATSHRMAPTPOLB | |
| SCHEMBL1543757 | 0.90 | POLB (0.55) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1544731 | 0.89 | CYP3A4 (0.59) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1544079 | 0.89 | LMNA (0.55) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1543530 | 0.88 | LMNA (0.57) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1543752 | 0.86 | CYP3A4 (0.54) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1544318 | 0.86 | LMNA (0.51) | CYP3A4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL1544111 | 0.85 | LMNA (0.47) | CYP3A4LMNAALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| WO-2005077345-A1 | COMPOUNDS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2005-08-25 | — | — | WO | claimed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7456200-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-11-25 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1723144-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| WO-2005077345-A1 | COMPOUNDS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2005-08-25 | — | — | WO | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | CYP3A4 41/4885LMNA 900/4885ALDH1A1 185/4885 |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | CYP3A4 4080/4885LMNA 4509/4885ALDH1A1 3875/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | CYP3A4 3566/4885LMNA 4511/4885ALDH1A1 2602/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | CYP3A4 4080/4885LMNA 4509/4885ALDH1A1 3875/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | CYP3A4 4080/4885LMNA 4509/4885ALDH1A1 3875/4885 |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | CYP3A4 4080/4885LMNA 4509/4885ALDH1A1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.